Economy

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Cut to "Buy" at Vetr Inc

Price targets show what analysts believes a stock will be worth at the end of a certain time period. A P/B ratio of less than 1.0 can indicate that a stock is undervalued, while a ratio of greater than 1.0 may indicate that a stock is overvalued.

In the most updated research from a number of analysts on Wall Street, the company gets 17 Buys and 0 Sell among 22 analysts.

Currently, 0.20% shares of The Estee Lauder Companies Inc. Zacks Investment Research cut Vertex Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, August 4th. Vertex Pharmaceuticals Incorporated has been given an analysts' mean target of 178.09. The stock closing price is now trading downward to its 50 day moving average with change of -5.96%, tumbled to its 20 day moving average with figure of -2.50% and behind its 200 day moving average with value -17.78%. Six equities research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company's stock.

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) opened at 157.215 on Tuesday. The overall volume in the last trading session was 9.1 million shares. Over the last five days, shares have faced -2.73% losses and now is up 41.27% since hitting its 200-day moving average of $125.51. The company has market cap of $40.04 billion. Vertex Pharmaceuticals has a 52-week low of $71.46 and a 52-week high of $167.85.

Vertex Pharmaceuticals Incorporated (VRTX) now has a Return on Assets (ROA) value of 8.8 Percent. The Return on Investment (ROI) ratio of Vertex Pharmaceuticals Incorporated (VRTX) is -0.3 percent. The company had revenue of $544.10 million for the quarter, compared to analysts' expectations of $489.95 million. The Regal Investment Advisors Llc holds 46,487 shares with $4.85M value, down from 50,297 last quarter. On average, analysts predict that Vertex Pharmaceuticals will post $1.60 EPS for the current fiscal year.

Sowell Financial Services LLC now owns 2,762 shares of the pharmaceutical company's stock worth $325,000 after acquiring an additional 23 shares in the last quarter. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & worldwide trademark & copyright legislation. The correct version of this story can be accessed at https://weekherald.com/2017/09/12/vertex-pharmaceuticals-incorporated-vrtx-stock-rating-lowered-by-vetr-inc.html. Finally, Morgan Stanley increased its stake in shares of Vertex Pharmaceuticals by 269.3% in the third quarter. The share price has moved forward from its 20 days moving average, trading at a distance of 1.95% and stays 5.92% away from its 50 days moving average. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The shares were sold at an average price of $90.00, for a total transaction of $108,720.00. The disclosure for this sale can be found here. Also, EVP Stuart A. Arbuckle sold 1,208 shares of the company's stock in a transaction that occurred on Wednesday, November 9th.

Several large investors have recently modified their holdings of the stock. Guardian Life Insurance Co. of America lifted its position in shares of Vertex Pharmaceuticals by 0.6% during the first quarter. Baillie Gifford & Co. grew its holdings in shares of Vertex Pharmaceuticals by 6.9% during the second quarter. The earnings per share (EPS) term represents portion of a company's earnings with net of taxes as well as preferred stock dividends that is owed to each share of common stock. Vanguard Group Inc. raised its holdings in Vertex Pharmaceuticals by 3.5% during the 1st quarter. Jennison Associates LLC now owns 5,055,122 shares of the pharmaceutical company's stock valued at $651,454,000 after buying an additional 3,626,368 shares during the period. Finally, RNC Capital Management LLC boosted its holdings in Vertex Pharmaceuticals by 5.3% in the second quarter. Tocqueville Asset Management L.P. purchased a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at about $203,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company.

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.



Like this

loading...
loading...

Latest


13 September 2017
Kathie Lee Gifford's mother Joan Epstein dies at 87
Kotb posted on her personal account a photo of her and Gifford with their mothers, writing "We will miss you sweet Joannie". She also opened up about how much her mother meant to her and how much she supported her in achieving her dreams.

13 September 2017
Target hiring thousands for holiday season
Target is hiring more than 100,000 temporary workers for the holidays - a sharp increase over past year . Hiring events for store positions will be held at each of Target's 1,816 stores from 10 a.m.to 6 p.m.

13 September 2017
Which insiders are trading TETRA Technologies, Inc. (TTI)?
Their average price target spell out an upbeat performance - a 104% and would give TTI a market capitalization of almost $502.13M. Paloma Ptnrs Management Co owns 38,026 shares. (NYSE:SE) has "Outperform" rating given on Monday, June 27 by RBC Capital Markets.

13 September 2017
Passionate Bellerin insists Arsenal focused on Cologne and Europa League, not Chelsea
That was disappointing as that would have been another good trophy to win. "We are a new squad". There are so many games to play.

13 September 2017
Ex-President Saakashvili pledges to tour Ukraine
Kiev is "panicking", Saakashvili said, adding that he did "not want to overthrow President Poroshenko" but just defend his rights. Surrounded by supporters, Saakashvili broke through a cordon of Ukrainian border guards at the Ukraine-Poland border Sunday.

13 September 2017
Should You Buy Finisar Corporation (NASDAQ:FNSR) On Current Analyst Views?
Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Lastly, Ameritas Investment Partners increased its position in stocks of Finisar Corporation by 5.5% in the 2nd period.

13 September 2017
After US Compromise, Security Council Strengthens North Korea Sanctions
Nor does the resolution impose a travel ban or asset freeze on Kim, as the original US draft had set out. Besides, the UN Security Council has also capped crude oil and refined petroleum products deliveries.

13 September 2017
Summit Midstream Partners, LP (NYSE:SMLP) Updated Broker Ratings
Analysts forecast that Magellan Midstream Partners L.P. will post $3.91 earnings per share for the current fiscal year. Sequoia Financial Advisors LLC raised its position in Magellan Midstream Partners L.P.by 352.8% in the second quarter.

13 September 2017
Brexit talks postponed to hand negotiators more flexibility: Britain
The Government is also offering to agree joint foreign policy positions with Brussels , including co-operating on worldwide sanctions against states or terrorist organisations.

13 September 2017
US Supreme Court Allows Trump's Broad Refugee Ban
The dispute concerned the reach of the high court's June ruling , which allowed the president's order to take partial effect. On the other hand, the court said, relationships formed for the goal of evading the travel ban did not count.